Cardiology Letters 2023, 32(4):281-291
Chronic cardiorenal syndrome
- II. kardiologickej klinika VÚSCH, a. s. a LF UPJŠ, Košice, Slovenská republika
The coexistence of cardiac and renal diseases is becoming more common in clinical practice. Patients with current cardiac and renal impairment have significantly higher morbidity and mortality. Cardiorenal syndrome is defined as impaired heart and kidney function, where acute or chronic dysfunction of one organ can induce acute or chronic dysfunction in the other, and it is divided into five subtypes. In chronic cardiorenal syndrome, chronic heart failure leads to damage or dysfunction of the kidneys. Several mechanisms are involved in the pathophysiology of cardiorenal syndrome: increased central venous and intraabdominal pressure, decreased cardiac output and cardiac index, neurohormonal dysregulation (activation of the sympathetic nervous system, renin-angiotensin-aldosterone system), oxidative stress, anemia, endocrine dysregulation, pro-inflammatory mediators and protein-binding uremic toxins. The cooperation of cardiologist and nephrologist is necessary in the diagnostic process and treatment of cardiorenal syndrome, while echocardiographic examination and ultrasonographic examination of the kidneys are the gold standard among imaging methods. The management and treatment of heart failure is based on the recommendations of the European Society of Cardiology for the diagnosis and treatment of acute and chronic heart failure. The treatment of chronic heart failure with concomitant renal impairment is not based on sufficient evidence, as these patients are generally excluded from the studies. Diuretic resistance is a clinical problem, which is common in these patients. Patients with advanced cardiorenal syndrome have a low quality of life and high mortality. They require a multidisciplinary approach, which should include palliative care.
Keywords: cardiorenal syndrome; heart failure; chronic kidney disease
Published: April 1, 2023 Show citation
References
- Ronco C, McCullough P, Anker S, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010;31:703-711.
Go to original source... - Santoro D, Gembillo G, Ando G. Glomerular filtration rate as a predictor of outcome in acute coronary syndrome complicated by atrial fibrillation. J Clin Med 2020;9:1466.
Go to original source... - Roger VL. Epidemiology of heart failure. Circ Res 2013;13:646659.
Go to original source... - Lorin J, Guilland JC, Stamboul K, Guenancia C, Cottin Y, Rochette L, et al. Increased symmetric dimethylarginine level is associated with worse hospital outcomes through altered left ventricular ejection fraction in patients with acute myocardial infarction. PLoS ONE, 2017;12,e0169979.
Go to original source... - Gembillo G, Visconti L, Giusti MA, Siligato R, Gallo A, Santoro D, et al. A cardiorenal syndrome: new pathways and novel biomarkers. Biomolecules 2021;11:1581.
Go to original source... - National Heart, Lung, and Blood Institute. NHLBI Working Group: Cardiorenal Connections in Heart Failure and Cardiovascular Disease. 2004. Dostupné online: https://www.nhlbi.nih.gov/events/2004/cardio-renal-connections-heartfailure-andcardiovascular-disease.
- Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, et. al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013;182:117-136.
Go to original source... - Writing committee members; Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:240-327.
- Ronco C, Bellasi A, Di Lulo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis 2018;25:382-390.
Go to original source... - Mann DL, Hassenfuss G. Chap 22-Pathophysiology of Heart failure in part IV Heart failure of Braunwald's Heart Diseases. Elsevier Saunders 2015.
- Kumar U, Garimella PS, Wettersten N. Cardiorenal syndromePathophysiology. Cardiol Clin 2019;37:251-265.
Go to original source... - Goffredo G, Barone R, Di Terlizzi V, Correale M, Brunetti ND, Iacoviello M.Biomarkers in Cardiorenal Syndrome. J Clin Med 2021;10:3433.
Go to original source... - Pinsino A, Mondellini GM, Royzman EA, Hoffman KL, D'Angelo D, Mabasa M, et al. Cystatin C- versus creatinine-based assessment of renal function and prediction of early outcomes among patients with a left ventricular assist device. Circ Heart Fail 2020;13,e006326.
Go to original source... - Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: Report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int 2020;97:1117-1129.
Go to original source... - Iacoviello M, Di Serio F, Rizzo C, Leone M, Grande D, Guida P, et al. Association between high Gal-3 serum levels and worsening of renal function in chronic heart failure outpatients. Biomark Med 2019;13:707-713.
Go to original source... - Grande D, Leone M, Rizzo C, Terlizzese P, Parisi G, Gioia MI, et al. A multiparametric approach Based on NT-proBNP, ST2, and Galectin3 for stratifying one year prognosis of chronic heart failure outpatients. J Cardiovasc Dev Dis 2017;4:9.
Go to original source... - Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int 2018;93:252-259.
Go to original source... - Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: An update. Theranostics 2018;8:593-609.
Go to original source... - McDonagh TA, Metra M, Adamo M, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2021;42:3599-3726.
Go to original source... - Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et.al. On behalf of the American heart association council on the kidney in cardiovascular disease and council on clinical cardiology. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment Strategies: A scientific statement from the American heart association. Circulation 2019;139:e840-e878.
Go to original source... - Thind GS, Loehrke M, Wilt JL. Acute cardiorenal syndrome: Mechanisms and clinical implications. Cleve Clin J Med 2018;85:231-239.
Go to original source... - Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco-Bacik MA, Wilson FP, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol 2017,28:3414-3424.
Go to original source... - Shah N, Madanieh R, Alkan M, Dogar MU, Kosmas CE, Vittorio TJ. A perspective on diuretic resistance in chronic congestive heart failure. Ther Adv Cardiovasc Dis 2017;11:271-278.
Go to original source... - McMurray JJ, Packer, M, Desai AS, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
Go to original source... - Velazquez EJ, Morrow DA, Devore AD, PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-548.
Go to original source... - Wachter R, Senni M, Belohlavek J, TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21:998-1007.
Go to original source... - Kang H, Zhang J, Zhang X, Qin G, Wang K, Deng Z, et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis. Eur J Pharmacol 2020;884:173444.
Go to original source... - Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation 2018;138:1505-1514.
Go to original source... - Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709717.
Go to original source... - Pitt B, Remme B, Zannad F. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
Go to original source... - Zanand F, McMurray JJ, Krum H, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
Go to original source... - Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 2017;46:213-221.
Go to original source... - Vukadinović D, Lavall D, Vukadinović AN, Pitt B, Wagenpfeil S, Böhm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J 2017;188:99-108.
Go to original source... - McMurray JJV, Solomon SD, Inzucchi SE, DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.
Go to original source... - Packer M, Anker SD, Butler J, EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424.
Go to original source... - Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPERORReduced and DAPA-HF trials. Lancet 2020;396:819-829.
Go to original source... - Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020;142:1040-1054.
Go to original source... - Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117-128.
Go to original source... - Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol 2021;20:236.
Go to original source... - Verma D, Firoz A, Garlapati SKP, Sai Charaan Reddy Sathi T, Haris M, Dhungana B, et al. Emerging Treatments of Cardiorenal Syndrome: An update on pathophysiology and management. Cureus 2021;13:e17240.
Go to original source... - Vítovec J, Špinar J, Špinarová L. Moderní trendy ve farmakologické léčbě srdečního selhání. Klinická farmakologie a farmacie 2021;35:54-59.
Go to original source... - Teerlink JR, Diaz R, Felker GM, GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2021;384:105-116.
Go to original source... - Armstrong PW, Pieske B, Anstrom KJ, VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020;382:1883-1893.
Go to original source... - Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial 2014;27:188-204.
Go to original source... - Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. JAMA 2017;318:1876-1890.
Go to original source... - O'Connor CM, Jiang W, Kuchibhatla M, SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-699.
Go to original source...

